SAN DIEGO, CA, USA I March 9, 2016 and NEW TAIPEI CITY, Taiwan I March 08, 2015 I Senhwa Biosciences, Inc. (“Senhwa” or the “Company”), a clinical-stage biotechnology company, today announced that it has entered into an agreement whereby Senwha will collaborate with Canadian Cancer Trials Group (CCTG)- sponsored phase I/II study of CX-5461 in patients with triple-negative breast cancer (TNBC) bearing either BRCA mutations or Homologous Recombination repair Deficiencies (HRD). The study is expected to begin enrolling patients in the second half of 2016.
CX-5461 is currently undergoing a phase I study in hematological malignancies in Australia. Treatment with CX-5461 has so far demonstrated a good safety profile and is well tolerated.
Conduct of the CCTG trial is supported by Senwha and is one of a series of trials supported by a Stand up to Cancer (SU2C) Canada-Canadian Breast Cancer Foundation Breast Cancer Dream Team translational research award.
MEDIA CONTACTS:
Senhwa Biosciences / Kenner Wang / kenner.wang@senhwabio.com / +886-2-89131956 ext. 216
About TNBC:
Triple-negative breast cancer is estimated to account for 10-20% of all diagnosed breast cancers and is characterized by a lack of expression of estrogen receptor (ER-), progesterone receptor (PR-) and HER2 (HER2-) on the breast cancer cells. TNBC remains a disease with poor prognosis due to the lack of targeted therapy.
About Canadian Cancer Trials Group (CCTG):
The CCTG is the only Canadian cooperative cancer trials group conducting the entire range of cancer trials from early phase studies to large international randomized controlled trials across all cancer types. Its primary mission is to assess the effectiveness of interventions to prevent the development of cancer or improve the care of those patients who do develop cancer. It is a national research program of the Canadian Cancer Society. Its Central Operations and Statistics Office is located at Queen’s University in Kingston, Ontario, Canada. For more information on CCTG, please visit https://www.ctg.queensu.ca/.
About Senhwa Biosciences, Inc.:
Senhwa Biosciences identifies and develops innovative therapies that have the potential to fundamentally change the way patients are treated. Our central philosophy is to unearth validated targets or therapies that could significantly improve cancer treatments, but have not yet been properly exploited. As a value-added development company, Senhwa aims to take innovative therapies that could impact the current standard of care and drive them through clinical Proof-of-Concept. Senhwa is headquartered in Taiwan, but with subsidiary located in San Diego, CA, the Senhwa Team is well positioned to oversee the development of their compounds by collaborating with a diverse range of global Investigators and service providers. Clinical trials are ongoing or planned for Australia, Canada, the USA and Asia, and service providers work from their bases in North America, Asia, Australia and Europe. For more information on Senhwa and its programs, please visit www.senhwabiosciences.com.
SOURCE: Senhwa Biosciences
Post Views: 27
SAN DIEGO, CA, USA I March 9, 2016 and NEW TAIPEI CITY, Taiwan I March 08, 2015 I Senhwa Biosciences, Inc. (“Senhwa” or the “Company”), a clinical-stage biotechnology company, today announced that it has entered into an agreement whereby Senwha will collaborate with Canadian Cancer Trials Group (CCTG)- sponsored phase I/II study of CX-5461 in patients with triple-negative breast cancer (TNBC) bearing either BRCA mutations or Homologous Recombination repair Deficiencies (HRD). The study is expected to begin enrolling patients in the second half of 2016.
CX-5461 is currently undergoing a phase I study in hematological malignancies in Australia. Treatment with CX-5461 has so far demonstrated a good safety profile and is well tolerated.
Conduct of the CCTG trial is supported by Senwha and is one of a series of trials supported by a Stand up to Cancer (SU2C) Canada-Canadian Breast Cancer Foundation Breast Cancer Dream Team translational research award.
MEDIA CONTACTS:
Senhwa Biosciences / Kenner Wang / kenner.wang@senhwabio.com / +886-2-89131956 ext. 216
About TNBC:
Triple-negative breast cancer is estimated to account for 10-20% of all diagnosed breast cancers and is characterized by a lack of expression of estrogen receptor (ER-), progesterone receptor (PR-) and HER2 (HER2-) on the breast cancer cells. TNBC remains a disease with poor prognosis due to the lack of targeted therapy.
About Canadian Cancer Trials Group (CCTG):
The CCTG is the only Canadian cooperative cancer trials group conducting the entire range of cancer trials from early phase studies to large international randomized controlled trials across all cancer types. Its primary mission is to assess the effectiveness of interventions to prevent the development of cancer or improve the care of those patients who do develop cancer. It is a national research program of the Canadian Cancer Society. Its Central Operations and Statistics Office is located at Queen’s University in Kingston, Ontario, Canada. For more information on CCTG, please visit https://www.ctg.queensu.ca/.
About Senhwa Biosciences, Inc.:
Senhwa Biosciences identifies and develops innovative therapies that have the potential to fundamentally change the way patients are treated. Our central philosophy is to unearth validated targets or therapies that could significantly improve cancer treatments, but have not yet been properly exploited. As a value-added development company, Senhwa aims to take innovative therapies that could impact the current standard of care and drive them through clinical Proof-of-Concept. Senhwa is headquartered in Taiwan, but with subsidiary located in San Diego, CA, the Senhwa Team is well positioned to oversee the development of their compounds by collaborating with a diverse range of global Investigators and service providers. Clinical trials are ongoing or planned for Australia, Canada, the USA and Asia, and service providers work from their bases in North America, Asia, Australia and Europe. For more information on Senhwa and its programs, please visit www.senhwabiosciences.com.
SOURCE: Senhwa Biosciences
Post Views: 27
